{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:38:53Z","timestamp":1770813533298,"version":"3.50.1"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Unlike typical categorical definitions of treatment-resistant depression (TRD) based on antidepressant (AD) trial failures, the Maudsley Staging Method (MSM) is a dimensional measure of resistance also rating episode duration, baseline depression severity and failure of augmentation strategies and ECT. However, MSM has not previously been used longitudinally across the full depressive episode, from episode onset to remission. We applied episode-wide MSM (EW-MSM) in patients with Major Depressive Disorder naturalistically followed to remission in a tertiary-care setting and categorized as 1\n                      <jats:sup>st<\/jats:sup>\n                      and 2\n                      <jats:sup>nd<\/jats:sup>\n                      AD trial remitters, TRD remitters and TRD non-remitters (categorical outcomes). The study aimed to investigate clinicodemographic and treatment-related correlates of EW-MSM and categorical outcomes, comparatively assess their predictive value for depression improvement, and explore the discriminative utility of EW-MSM across categorical outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We recruited 267 patients. EW-MSM was scored at remission (MADRS \u2264 9 in two consecutive visits), if achieved. Associations of clinicodemographic and treatment-related characteristics with EW-MSM and categorical outcomes were explored in multivariate models. Their comparative predictive value for depression improvement was tested in hierarchical linear regressions. ROC curves assessed EW-MSM discriminative utility across categorical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Analysis focused on 233 remitters (105 1\n                      <jats:sup>st<\/jats:sup>\n                      AD trial remitters, 62 2\n                      <jats:sup>nd<\/jats:sup>\n                      AD trial remitters and 66 TRD remitters). Both EW-MSM and categorical outcomes were associated with baseline severity, obsessive-compulsive disorder comorbidity, episode duration, number of ADs or AD combination. EW-MSM was additionally associated with psychotic features and use of augmentation strategies. EW-MSM was more strongly associated with baseline severity than categorical outcomes (R\n                      <jats:sup>2<\/jats:sup>\n                      = 0.24 vs. 0.14) and consequently predicted depression improvement to remission more efficiently in hierarchical regressions (\u0394R\n                      <jats:sup>2<\/jats:sup>\n                      = 0.13 vs. 0.05). EW-MSM discriminated well TRD remitters from 1\n                      <jats:sup>st<\/jats:sup>\n                      AD trial remitters (AUC = 0.91, 95% CI = 0.86-0.95) or from early remitters combined (AUC = 0.865, 95% CI = 0.81-0.92) but not among adjacent categories.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations<\/jats:title>\n                    <jats:p>Single, tertiary-care setting, unavailability of ECT\/esketamine and exclusion of patients on psychotherapy (not rated by MSM) limit study generalizability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>EW-MSM reflects clinical and treatment intensity aspects of resistance in depression more strongly and comprehensively than categorical outcomes. Therefore, it offers precision for staging and could be used to more efficiently investigate clinical, biological and psychological correlates of resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1769246","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:50:47Z","timestamp":1770792647000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Episode-wide Maudsley staging in treatment-resistant depression: a longitudinal tertiary-care comparison of dimensional and categorical outcomes"],"prefix":"10.3389","volume":"17","author":[{"given":"Anastasia","family":"Antoniou","sequence":"first","affiliation":[{"name":"2nd Department of Psychiatry, National and Kapodistrian University of Athens, \u201cAttikon\u201d University General Hospital","place":["Athens, Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Pappa","sequence":"additional","affiliation":[{"name":"Department of Brain Sciences, Faculty of Medicine, Imperial College London","place":["London, United Kingdom"]},{"name":"West London NHS Trust","place":["London, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Dikeos","sequence":"additional","affiliation":[{"name":"1st Department of Psychiatry, National and Kapodistrian University of Athens, Eginition Hospital","place":["Athens, Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Smyrnis","sequence":"additional","affiliation":[{"name":"2nd Department of Psychiatry, National and Kapodistrian University of Athens, \u201cAttikon\u201d University General Hospital","place":["Athens, Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Mendlevicz","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Libre de Bruxelles","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Serretti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Kore University of Enna","place":["Enna, Italy"]},{"name":"Oasi Research Institute-IRCCS","place":["Troina, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Cleare","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London","place":["London, United Kingdom"]},{"name":"South London and Maudsley NHS Foundation Trust","place":["London, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Ferentinos","sequence":"additional","affiliation":[{"name":"2nd Department of Psychiatry, National and Kapodistrian University of Athens, \u201cAttikon\u201d University General Hospital","place":["Athens, Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"James","year":"2018","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1192\/bjo.2023.627","article-title":"Care pathways, prescribing practices and treatment outcomes in major depressive disorder and treatment-resistant depression: retrospective, population-based cohort study","volume":"10","author":"Pappa","year":"2024","journal-title":"BJPsych Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.12.044","article-title":"Comorbidity and healthcare utilization in patients with treatment resistant depression: A large-scale retrospective cohort analysis using electronic health records","volume":"324","author":"Adekkanattu","year":"2023","journal-title":"J Affect Disord"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.3860","article-title":"Association of treatment-resistant depression with patient outcomes and health care resource utilization in a population-wide study","volume":"80","author":"Lundberg","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.11.124","article-title":"Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics","volume":"283","author":"Heerlein","year":"2021","journal-title":"J Affect Disord"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.12.090","article-title":"Health-related quality of life burden associated with treatment-resistant depression in UK patients: Quantitative results from a mixed-methods non-interventional study","volume":"300","author":"Rathod","year":"2022","journal-title":"J Affect Disord"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13699","article-title":"The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States","volume":"82","author":"Zhdanava","year":"2021","journal-title":"J Clin Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.03.029","article-title":"Treatment patterns in patients with treatment-resistant depression in Danish patients with major depressive disorder","volume":"287","author":"Gronemann","year":"2021","journal-title":"J Affect Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2018.04.016","article-title":"Treatment-resistant depression and suicidality","volume":"235","author":"Bergfeld","year":"2018","journal-title":"J Affect Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2024.11.022","article-title":"Health-care utilisation and associated economic burden in major depressive disorder and treatment-resistant depression in a longitudinal population-based cohort study of 110.000 patients","volume":"180","author":"Pappa","year":"2024","journal-title":"J Psychiatr Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.euroneuro.2007.03.009","article-title":"What is the meaning of treatment resistant\/refractory major depression (TRD)? A systematic review of current randomized trials","volume":"17","author":"Berlim","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jad.2011.02.020","article-title":"Staging methods for treatment resistant depression","volume":"137","author":"Ruh\u00e9","year":"2012","journal-title":"A systematic review. J Affect Disord"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01381-x","article-title":"A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials","volume":"27","author":"Sforzini","year":"2022","journal-title":"Mol Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1588902","article-title":"Editorial: Treatment resistant depression (TRD): epidemiology, clinic, burden and treatment","volume":"16","author":"Fiorillo","year":"2025","journal-title":"Front Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/ijnp\/pyy052","article-title":"The impact of (the concept of) treatment-resistant depression: an opinion review","volume":"22","author":"Demyttenaere","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"B17","volume-title":"Guideline on clinical investigation of medicinal products in the treatment of depression","year":"2013"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/15622970801981606","article-title":"Outcomes in major depressive disorder: The evolving concept of remission and its implications for treatment","volume":"9","author":"M\u00f6ller","year":"2008","journal-title":"World J Biol Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s0197-2456(03)00112-0","article-title":"Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design","volume":"25","author":"Rush","year":"2004","journal-title":"Control Clin Trials"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1017\/s1092852915000826","article-title":"Treating to target in major depressive disorder: response to remission to functional recovery","volume":"20","author":"McIntyre","year":"2015","journal-title":"CNS Spectr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12888-018-1679-x","article-title":"Standardisation framework for the Maudsley staging method for treatment resistance in depression","volume":"18","author":"Fekadu","year":"2018","journal-title":"BMC Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18r12250","article-title":"Staging treatment intensity and defining resistant depression: historical overview and future directions","volume":"80","author":"Salloum","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"B24","article-title":"When at first you don\u2019t succeed: sequential strategies for antidepressant nonresponders","volume":"58","author":"Thase","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2019.1635270","article-title":"Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice","volume":"20","author":"Bartova","year":"2019","journal-title":"World J Biol Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/s0924-977x(98)00004-2","article-title":"Treatment resistant depression: methodological overview and operational criteria","volume":"9","author":"Souery","year":"1999","journal-title":"Eur Neuropsychopharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.08m04309","article-title":"A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method","volume":"70","author":"Fekadu","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04728","article-title":"The Maudsley Staging Method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms","volume":"70","author":"Fekadu","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"22060","DOI":"10.4088\/JCP.17m11475","article-title":"Validity of the Maudsley Staging Method in predicting treatment-resistant depression outcome using the Netherlands study of depression and anxiety","volume":"79","author":"Van Belkum","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.03.002","article-title":"Predictive value of baseline resistance in early response to antidepressants","volume":"161","author":"Icick","year":"2014","journal-title":"J Affect Disord"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.102665","article-title":"Prediction of longer-term outcome of treatment-resistant depression in tertiary care","volume":"201","author":"Fekadu","year":"2012","journal-title":"Br J Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12962","article-title":"The Maudsley Staging Method as predictor of electroconvulsive therapy effectiveness in depression","volume":"138","author":"van Diermen","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"B33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.comppsych.2017.06.007","article-title":"Validating a two-dimensional bipolar spectrum model integrating DSM-5\u2019s mixed features specifier for Major Depressive Disorder","volume":"77","author":"Ferentinos","year":"2017","journal-title":"Compr Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00857-4","article-title":"Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology","volume":"53","author":"Mullins","year":"2021","journal-title":"Nat Genet"},{"key":"B35","volume-title":"Structured clinical interview for DSM-5 disorders: Clinician Version (SCID-5-CV)","author":"First","year":"2016"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1192\/bjp.148.5.599","article-title":"Grade scores of the montgomery-asberg depression and the clinical anxiety scales","volume":"148","author":"Snaith","year":"1986","journal-title":"Br J Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2015.03.021","article-title":"Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials","volume":"180","author":"Hayasaka","year":"2015","journal-title":"J Affect Disord"},{"key":"B39","unstructured":"ATC (Anatomical Therapeutic Chemical)\/DDD (Defined Daily Dose) Index 2025\n          \n          2025"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"B41","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s0165-0327(01)00451-7","article-title":"Defining remission by cut off score on the MADRS: selecting the optimal value","volume":"72","author":"Hawley","year":"2002","journal-title":"J Affect Disord"},{"key":"B43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1055\/a-1841-6672","article-title":"Linkage of young mania rating scale to clinical global impression scale to enhance utility in clinical practice and research trials","volume":"56","author":"Samara","year":"2023","journal-title":"Pharmacopsychiatry"},{"key":"B44","volume-title":"Stata Statistical Software: Release 14","year":"2015"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12870","article-title":"Clinical correlates of augmentation\/combination treatment strategies in major depressive disorder","volume":"137","author":"Dold","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"B46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.euroneuro.2025.06.011","article-title":"Clinical predictors of treatment resistant depression","volume":"98","author":"Serretti","year":"2025","journal-title":"Eur Neuropsychopharmacol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v68n0713","article-title":"Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study","volume":"68","author":"Souery","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2021.110285","article-title":"Melancholic features in major depression - a European multicenter study","volume":"110","author":"Dold","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-021-01368-3","article-title":"The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries","volume":"272","author":"Fugger","year":"2022","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2014.987814","article-title":"What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram","volume":"16","author":"Souery","year":"2015","journal-title":"World J Biol Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.65.8.870","article-title":"Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features","volume":"65","author":"Rush","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2015.09.033","article-title":"Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study","volume":"189","author":"Balestri","year":"2016","journal-title":"J Affect Disord"},{"key":"B53","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/acps.12959","article-title":"Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study","volume":"139","author":"Kautzky","year":"2019","journal-title":"Acta Psychiatr Scand"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.10.033","article-title":"Low comorbid obsessive-compulsive disorder in patients with major depressive disorder - Findings from a European multicenter study","volume":"227","author":"Dold","year":"2018","journal-title":"J Affect Disord"},{"key":"B55","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/ijnp\/pyy024","article-title":"The genetics of treatment-resistant depression: A critical review and future perspectives","volume":"22","author":"Fabbri","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/104012371302500204","article-title":"Treatment resistance in severe unipolar depression: no association with psychotic or melancholic features","volume":"25","author":"Zaninotto","year":"2013","journal-title":"Ann Clin Psychiatry"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyy009","article-title":"Major depression and the degree of suicidality: results of the european group for the study of resistant depression (GSRD)","volume":"21","author":"Dold","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyae055","article-title":"Anhedonia is associated with a specific depression profile and poor antidepressant response","volume":"27","author":"Luca","year":"2024","journal-title":"Int J Neuropsychopharmacol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1192\/bjp.2018.233","article-title":"Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis","volume":"214","author":"Strawbridge","year":"2019","journal-title":"Br J Psychiatry"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221104058","article-title":"Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression","volume":"37","author":"Scott","year":"2023","journal-title":"J Psychopharmacol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.euroneuro.2021.11.005","article-title":"A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response","volume":"55","author":"Fanelli","year":"2022","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1769246\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:50:49Z","timestamp":1770792649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1769246\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":61,"alternative-id":["10.3389\/fpsyt.2026.1769246"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1769246","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"article-number":"1769246"}}